<DOC>
	<DOC>NCT01658722</DOC>
	<brief_summary>A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.</brief_summary>
	<brief_title>Retrieval of Patient Information After Discontinuation</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1. Signed, dated, and written informed consent obtained from the subject and/or the subject's legally acceptable representative (LAR, if applicable) in accordance with local regulations. 2. Signed, dated, and written informed consent, obtained from the subject's caregiver in accordance with local regulations. 3. Subject must have participated in the Study 301, 302, or 351 and have received at least 1 dose of study treatment (bapineuzumab or placebo). 4. Subject must have been off treatment for at least 12 months prior to Visit 1. 5. Subjects must have a primary caregiver for the duration of the study. 6. Subject's caregiver must have the ability to assess the subject and answer questions over the phone.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>